Clinical trials: Asymptomatic Infections
Malaria,Falciparum
Evaluation of Community-based Mass Screening and Treatment for Malaria in Western Kenya
This study is a cluster-randomized controlled trial to evaluate the efficacy of community-based mass screening with a malaria rapid diagnostic test, and treatment of participants with positive tests with an appropriate…
- Trial name
- MSaT (NCT02987270)
- Testing
- Dihydroartemisinin-piperaquine
- Volunteers
- 90,000 people, healthy volunteers welcome
- Sponsor
- Simon Kariuki
Preterm Birth, Small for Gestational Age (SGA)
Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
This study, Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries (ABLE), is designed as a 2-arm randomized controlled trial (RCT) focused on pregnant individuals and newborn infants.
- Conditions
- Preterm Birth, Small for Gestational Age (SGA), Stillbirth, Bacteriuria (Asymptomatic) in Pregnancy
- Trial name
- ABLE (NCT06723392)
- Testing
- Oral nitrofurantoin monohydrate/macrocrystals
- Where
- 7 sites in Bangladesh, Democratic Republic of the Congo and 4 more
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- NICHD Global Network for Women's and Children's Health
Covid19, SARS-CoV-2
SARS-CoV-2 /COVID-19 Admission Screening in a University Hospital Setting
The proportion of asymptomatic carriers of SARS-CoV-2 remains elusive, so the potential benefit of systematic screening during the SARS-CoV-2-pandemic is controversial.
- Trial name
- NCT04519372
- Testing
- Testing for SARS-CoV-2
- Where
- Switzerland
- Volunteers
- 4,099 people
- Sponsor
- University Hospital, Basel, Switzerland
HIV
Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults
The proposed research will include adolescent and young adult Hispanic/Latino men who have sex with men (MSM) and heterosexual men and women, aged 13-24 years, and will be based at 13 ATN Adolescent Medicine Trial Units (AMTUs)…
- Trial name
- NCT01203332
- Testing
- Effectiveness of different strategies in HIV testing and linkage to care
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 1,917 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Visceral Leishmaniasis
A Community Trial for Visceral Leishmaniasis (VL)
Visceral leishmaniasis (VL) / Kala-azar (KA) is a public health problem in the many countries in the world including Bangladesh. Where more than 90,000 VL cases have been reported since 1994. The disease is fatal if not treated.
- Trial name
- NCT01069198
- Testing
- Albendazole, Iron, Zinc and Vitamin A
- Where
- 2 sites in Bangladesh
- Volunteers
- 200 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
HIV Infections
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy
To confirm results from a previous study in which the combination of thymopentin plus zidovudine ( AZT ), an antiretroviral agent, slowed disease progression in HIV-infected asymptomatic patients.
- Trial name
- NCT00002109
- Testing
- Thymopentin, Stavudine, Zidovudine
- Where
- 50 sites in United States, Puerto Rico
- Sponsor
- Immunobiology Research Institute
Influenza
Asymptomatic Flu Project
Although clinical presentation of influenza is often symptomatic, asymptomatic cases also occur. The knowledge of the incidence of asymptomatic influenza among healthcare workers is very important because of the risk of…
- Trial name
- AFP (NCT02868658)
- Testing
- Blood sampling, Nasal swab
- Where
- France
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm
Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)
This phase II trial studies the effects of ibrutinib in treating patients with B-cell malignancies who are infected with COVID-19.
- Conditions
- Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT04665115
- Testing
- Ibrutinib, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Academic and Community Cancer Research United
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects
This protocol represents the first in human study of TUTI-16, and is being conducted to establish the safety and human immunogenicity (anti-HIV-1 Tat titers) of subcutaneously administered TUTI-16.
- Trial name
- THYMON-08001 (NCT00848211)
- Testing
- TUTI-16 (0.03mg), TUTI-16 (0.1mg), TUTI-16 (0.6mg)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Thymon, LLC
SARS CoV 2 Infection
Rutgers Pilot for PREDICT- Patient POC Test
A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral antigen using a point-of-care (POC) Rapid…
- Trial name
- NCT05612724
- Testing
- Testing for SARS CoV2 Antigen
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
HIV Infections
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
AMENDED: To investigate whether subcutaneous (SC) injection of IL-2 produces biological responses which parallel those observed with IV dosing.
- Trial name
- NCT00001005
- Testing
- Zidovudine, Aldesleukin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Drug Resistant Malaria, Asymptomatic Infections
Drug Resistance Among Asymptomatic Infection
A cross-sectional study will be conducted in selected 2 sentinel sites for assessment of drug resistance falciparum and vivax among asymptomatic infection in migrant workers in Myanmar.
- Conditions
- Drug Resistant Malaria, Asymptomatic Infections, Migrant Workers
- Trial name
- NCT03648411
- Testing
- Drug resistance molecular markers
- Where
- Burma
- Volunteers
- 765 people, healthy volunteers welcome
- Sponsor
- Department of Medical Research, Lower Myanmar
Malaria
Transmission Dynamics of Residual and Re-emerging Malaria in the Amazon: Defining a Roadmap to Malaria Elimination
A population baseline longitudinal study in a major residual malaria hotspot in Brazil to: 1. identify risk factors for residual malaria infection and disease at individual and household level, 2.
- Trial name
- NCT03689036
- Where
- Brazil
- Volunteers
- 2,000 people
- Sponsor
- Oswaldo Cruz Foundation
Malaria, Parasitic Infection
Infections in Migrants in Sweden - the Importance of Malaria and Other Parasitic Infections
Malaria is a parasitic disease causing substantial morbidity and mortality globally. Malaria is a potentially severe and fatal disease in non-immune individuals.
- Trial name
- MMS (NCT05086887)
- Testing
- Malaria diagnostic tests (RDT and PCR) and serology for malaria and other parasitic diseases
- Where
- Sweden
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- Region Stockholm
Asymptomatic Infections, SARS-CoV2 Infection
Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection
This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic carrier of SAR-CoV2 adult Thai…
- Trial name
- IDRA-COVID19 (NCT04435587)
- Testing
- Ivermectin Pill, Combined ART/hydroxychloroquine
- Where
- 4 sites in Thailand
- Volunteers
- 80 people
- Sponsor
- Mahidol University
Covid19
Phase 3 Clinical Study Evaluating Nitric Oxide Nasal Spray (NONS) Efficacy To Treat and Prevent the Exacerbation of Infection in Individuals With Documented Asymptomatic or Mild COVID-19
Study Design: This is a double-blind, placebo-controlled, Phase 3 clinical efficacy study evaluating NONS in adult volunteers as a treatment for high-risk asymptomatic and symptomatic individuals with mild COVID-19 infection.
- Trial name
- NCT05012319
- Testing
- to be given as a treatment
- Where
- Bahrain
- Volunteers
- 500 people
- Sponsor
- Salmaniya Medical Complex
COVID-19 Respiratory Infection, SARS-CoV-2 Acute Respiratory Disease
Photodynamic Therapy for COVID-19 Prevention
This is a single-center open-label study to evaluate antimicrobial photodynamic therapy (aPDT) for upper airway decolonization in patients presenting with SARS-CoV-2 positive antigen test with mild or no symptoms of COVID-19.
- Trial name
- NCT05184205
- Testing
- Nasal Photodisinfection
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Ondine Biomedical Inc.
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
- Trial name
- NCT01335191
- Testing
- TUTI-16 (1.0 mg)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Thymon, LLC
Malaria, Falciparum, Malaria, Asymptomatic Parasitaemia
MDA and Targeted Control Against Plasmodium Carriage in the Sahel
Strategies implemented since 2010 by the Senegalese National Malaria Control Program (NMCP) enabled a reduction of malaria transmission.
- Trial name
- AMARETI (NCT07281443)
- Testing
- MDA with DHAp and SLD Primaquine, Targeted control (10-24 years) during the malaria high tranmission season: behaviour, Targeted control (15-24 years) during the malaria high tranmission season: test and treat
- Where
- Senegal
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
HIV Infections
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals
To determine the safety and immunogenicity of vaccinia-derived HIV-1 recombinant envelope glycoprotein (gp160) in asymptomatic HIV-infected adult volunteers.
- Trial name
- NCT00000633
- Testing
- gp160 Vaccine (Immuno-AG), Hepatitis B Vaccine (Recombinant)
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)